• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

突变型和野生型肺癌细胞的放射敏感性差异在较低剂量时更大。

Radiosensitivity Differences between Mutant and Wild-Type Lung Cancer Cells are Larger at Lower Doses.

机构信息

Department of Radiation Oncology, Gunma University Graduate School of Medicine, Maebashi 371-8511, Japan.

Division of Radiation Oncology, Department of Radiology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.

出版信息

Int J Mol Sci. 2019 Jul 25;20(15):3635. doi: 10.3390/ijms20153635.

DOI:10.3390/ijms20153635
PMID:31349558
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6696360/
Abstract

In the era of precision medicine, radiotherapy strategies should be determined based on genetic profiles that predict tumor radiosensitivity. Accordingly, pre-clinical research aimed at discovering clinically applicable genetic profiles is needed. However, how a given genetic profile affects cancer cell radiosensitivity is unclear. To address this issue, we performed a pilot in vitro study by utilizing mutational status as a model for genetic profile. Clonogenic assays of mutant ( = 6) and wild-type ( = 9) non-small cell lung carcinoma (NSCLC) cell lines were performed independently by two oncologists. Clonogenic survival parameters SF, SF, SF, SF, mean inactivation dose (MID), D, D, α, and β were obtained using the linear quadratic model. The differences in the clonogenic survival parameters between the mutant and wild-type cell lines were assessed using the Mann-Whitney U test. As a result, for both datasets, the values for SF, SF, D, α, and α/β were below 0.05, and those for SF were lowest. These data indicate that a genetic profile of NSCLC cell lines might be predictive for their radiation response; i.e., mutant cell lines might be more sensitive to low dose- and low fraction sized-irradiation.

摘要

在精准医学时代,放疗策略应基于预测肿瘤放射敏感性的基因谱来确定。因此,需要开展临床前研究以发现具有临床应用价值的基因谱。然而,特定的基因谱如何影响癌细胞的放射敏感性尚不清楚。为了解决这个问题,我们进行了一项体外初步研究,利用突变状态作为基因谱的模型。由两位肿瘤学家分别独立对突变型(n=6)和野生型(n=9)非小细胞肺癌(NSCLC)细胞系进行集落形成试验。采用线性二次模型获得集落形成存活参数 SF、SF、SF、SF、平均失活剂量(MID)、D、D、α 和β。使用曼-惠特尼 U 检验评估突变型和野生型细胞系之间集落形成存活参数的差异。结果,对于两个数据集,SF、SF、D、α 和 α/β 的 SF 值均低于 0.05,而 SF 的 SF 值最低。这些数据表明 NSCLC 细胞系的基因谱可能对其辐射反应具有预测性;即突变型细胞系可能对低剂量和小分割照射更敏感。

相似文献

1
Radiosensitivity Differences between Mutant and Wild-Type Lung Cancer Cells are Larger at Lower Doses.突变型和野生型肺癌细胞的放射敏感性差异在较低剂量时更大。
Int J Mol Sci. 2019 Jul 25;20(15):3635. doi: 10.3390/ijms20153635.
2
Robustness of Clonogenic Assays as a Biomarker for Cancer Cell Radiosensitivity.克隆集落形成分析作为癌症细胞放射敏感性生物标志物的稳健性。
Int J Mol Sci. 2019 Aug 25;20(17):4148. doi: 10.3390/ijms20174148.
3
Radiosensitivity and TP 53, EGFR amplification and LOH10 analysis of primary glioma cell cultures.原发性胶质瘤细胞培养物的放射敏感性以及TP 53、表皮生长因子受体(EGFR)扩增和10号染色体杂合性缺失(LOH10)分析
Strahlenther Onkol. 2002 Sep;178(9):491-6. doi: 10.1007/s00066-002-0952-5.
4
Fractionated irradiation of five human lung cancer cell lines and prediction of survival according to a radiobiology model.分阶段照射五种人肺癌细胞系,并根据放射生物学模型预测生存情况。
Anticancer Res. 2011 Apr;31(4):1125-30.
5
Radiosensitivity of new and established human melanoma cell lines: comparison of [3H]thymidine incorporation and soft agar clonogenic assays.新的和已建立的人黑色素瘤细胞系的放射敏感性:[3H]胸苷掺入法和软琼脂克隆形成试验的比较
Eur J Cancer. 1994;30A(9):1370-6. doi: 10.1016/0959-8049(94)90188-0.
6
Potential application of the ATP cell viability assay in the measurement of intrinsic radiosensitivity in cervical cancer.ATP细胞活力测定法在宫颈癌内在放射敏感性测量中的潜在应用。
Gynecol Oncol. 2005 Mar;96(3):765-70. doi: 10.1016/j.ygyno.2004.11.025.
7
Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation.具有表皮生长因子受体激酶结构域突变的非小细胞肺癌对电离辐射敏感。
Cancer Res. 2006 Oct 1;66(19):9601-8. doi: 10.1158/0008-5472.CAN-06-2627.
8
Relationships between clonogenic cell survival, DNA damage and chromosomal radiosensitivity in nine human cervix carcinoma cell lines.九种人宫颈癌细胞系中克隆源性细胞存活、DNA损伤与染色体放射敏感性之间的关系
Int J Radiat Biol. 2001 Mar;77(3):295-302. doi: 10.1080/09553000010017108.
9
Dose fractionation effects in primary and metastatic human uveal melanoma cell lines.原发性和转移性人葡萄膜黑色素瘤细胞系中的剂量分割效应。
Invest Ophthalmol Vis Sci. 2003 Nov;44(11):4660-4. doi: 10.1167/iovs.03-0151.
10
Comparison of sulforhodamine B, tetrazolium and clonogenic assays for in vitro radiosensitivity testing in human ovarian cell lines.用于人卵巢细胞系体外放射敏感性测试的磺酰罗丹明B、四氮唑和克隆形成试验的比较
Anticancer Drugs. 1995 Feb;6(1):115-23. doi: 10.1097/00001813-199502000-00014.

引用本文的文献

1
Outcomes of patients receiving urgent palliative radiotherapy for advanced lung cancer: an observational study.晚期肺癌患者接受紧急姑息性放疗的结果:一项观察性研究。
BMC Palliat Care. 2024 Dec 21;23(1):296. doi: 10.1186/s12904-024-01628-8.
2
Establishment of cancer cell radiosensitivity database linked to multi-layer omics data.建立与多层组学数据相关联的癌细胞放射敏感性数据库。
Cancer Sci. 2025 Mar;116(3):690-697. doi: 10.1111/cas.16334. Epub 2024 Dec 12.
3
Genetic profiling in radiotherapy: a comprehensive review.放射治疗中的基因谱分析:全面综述

本文引用的文献

1
Inter-assay precision of clonogenic assays for radiosensitivity in cancer cell line A549.癌细胞系A549放射敏感性克隆形成试验的批间精密度
Oncotarget. 2018 Feb 7;9(17):13706-13712. doi: 10.18632/oncotarget.24448. eCollection 2018 Mar 2.
2
A Comprehensive Infrastructure for Big Data in Cancer Research: Accelerating Cancer Research and Precision Medicine.癌症研究中的大数据综合基础设施:加速癌症研究与精准医学
Front Cell Dev Biol. 2017 Sep 21;5:83. doi: 10.3389/fcell.2017.00083. eCollection 2017.
3
Tumour radiosensitivity is associated with immune activation in solid tumours.
Front Oncol. 2024 Jul 26;14:1337815. doi: 10.3389/fonc.2024.1337815. eCollection 2024.
4
The efficacy of postoperative radiotherapy in resected pⅢA-N2 EGFR mutant and wild-type lung adenocarcinoma.术后放疗对切除的ⅢA-N2期表皮生长因子受体(EGFR)突变型和野生型肺腺癌的疗效。
iScience. 2024 Jun 8;27(7):110219. doi: 10.1016/j.isci.2024.110219. eCollection 2024 Jul 19.
5
DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors.DB-1310 是一种抗体偶联药物(ADC),由一种新型抗 HER3 抗体与一种 DNA 拓扑异构酶 I 抑制剂偶联而成,对治疗 HER3 阳性实体瘤具有高度疗效。
J Transl Med. 2024 Apr 17;22(1):362. doi: 10.1186/s12967-024-05133-7.
6
Comparison of Efficacy and Safety of First-Line Treatment Options for Unresectable Stage III Non-Small Cell Lung Cancer: A Retrospective Analysis.不可切除的 III 期非小细胞肺癌一线治疗方案的疗效与安全性比较:一项回顾性分析
Int J Clin Pract. 2024 Feb 12;2024:8585035. doi: 10.1155/2024/8585035. eCollection 2024.
7
Differences in Radiosensitivity According to EGFR Mutation Status in Non-Small Cell Lung Cancer: A Clinical and In Vitro Study.非小细胞肺癌中根据表皮生长因子受体(EGFR)突变状态的放射敏感性差异:一项临床与体外研究
J Pers Med. 2023 Dec 25;14(1):25. doi: 10.3390/jpm14010025.
8
Management of locally advanced non-small cell lung cancer: State of the art and future directions.局部晚期非小细胞肺癌的治疗:现状与未来方向。
Cancer Commun (Lond). 2024 Jan;44(1):23-46. doi: 10.1002/cac2.12505. Epub 2023 Nov 20.
9
Value of carbon-ion radiotherapy for early stage non-small cell lung cancer.碳离子放射治疗对早期非小细胞肺癌的价值
Clin Transl Radiat Oncol. 2022 Jun 14;36:16-23. doi: 10.1016/j.ctro.2022.06.005. eCollection 2022 Sep.
10
How to Improve SBRT Outcomes in NSCLC: From Pre-Clinical Modeling to Successful Clinical Translation.如何改善非小细胞肺癌的立体定向体部放疗效果:从临床前建模到成功的临床转化
Cancers (Basel). 2022 Mar 27;14(7):1705. doi: 10.3390/cancers14071705.
实体瘤中的肿瘤放射敏感性与免疫激活相关。
Eur J Cancer. 2017 Oct;84:304-314. doi: 10.1016/j.ejca.2017.08.001. Epub 2017 Aug 29.
4
CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531.CD33剪接多态性决定初治急性髓系白血病中吉妥珠单抗奥唑米星的疗效:儿童肿瘤协作组III期随机试验AAML0531的报告
J Clin Oncol. 2017 Aug 10;35(23):2674-2682. doi: 10.1200/JCO.2016.71.2513. Epub 2017 Jun 23.
5
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.奥拉帕利治疗携种系 BRCA 突变的转移性乳腺癌患者。
N Engl J Med. 2017 Aug 10;377(6):523-533. doi: 10.1056/NEJMoa1706450. Epub 2017 Jun 4.
6
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.肺腺癌的前瞻性综合分子特征分析,以实现患者与已批准和新兴疗法的有效匹配。
Cancer Discov. 2017 Jun;7(6):596-609. doi: 10.1158/2159-8290.CD-16-1337. Epub 2017 Mar 23.
7
Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study.肿瘤分子谱分析用于指导晚期儿童实体瘤治疗决策的多中心可行性研究:个体化癌症治疗(iCat)研究
JAMA Oncol. 2016 May 1;2(5):608-615. doi: 10.1001/jamaoncol.2015.5689.
8
Integration of a Radiosensitivity Molecular Signature Into the Assessment of Local Recurrence Risk in Breast Cancer.将放射敏感性分子特征纳入乳腺癌局部复发风险评估
Int J Radiat Oncol Biol Phys. 2015 Nov 1;93(3):631-8. doi: 10.1016/j.ijrobp.2015.06.021. Epub 2015 Jun 25.
9
The radiosensitivity index predicts for overall survival in glioblastoma.放射敏感性指数可预测胶质母细胞瘤的总生存期。
Oncotarget. 2015 Oct 27;6(33):34414-22. doi: 10.18632/oncotarget.5437.
10
Radiosensitivity index predicts for survival with adjuvant radiation in resectable pancreatic cancer.放射敏感性指数可预测可切除胰腺癌辅助放疗后的生存情况。
Radiother Oncol. 2015 Oct;117(1):159-64. doi: 10.1016/j.radonc.2015.07.018. Epub 2015 Jul 30.